You are here

  • Home
  • Archive
  • Volume 5, Issue 2
  • Patient-reported outcomes for tofacitinib with and without methotrexate, or adalimumab with methotrexate, in rheumatoid arthritis: a phase IIIB/IV trial

Article metrics

Article menu

Download PDFPDF

Rheumatoid arthritis
Original article
Patient-reported outcomes for tofacitinib with and without methotrexate, or adalimumab with methotrexate, in rheumatoid arthritis: a phase IIIB/IV trial

 

Online download statistics by month:

Online download statistics by month: October 2019 to September 2024

AbstractFullPdf
Oct 2019523506174
Nov 2019264258112
Dec 201912612648
Jan 202010710545
Feb 2020999725
Mar 20209291601
Apr 202015315130
May 2020848364
Jun 2020898960
Jul 2020656542
Aug 2020776757
Sep 20201069160
Oct 2020979154
Nov 20201049443
Dec 2020868226
Jan 2021848036
Feb 2021898545
Mar 20211009753
Apr 2021908448
May 2021686527
Jun 2021706741
Jul 2021545150
Aug 2021555422
Sep 2021575148
Oct 2021858453
Nov 2021565545
Dec 2021858637
Jan 2022413816
Feb 2022596835
Mar 2022909255
Apr 2022989955
May 2022747751
Jun 2022535325
Jul 2022575522
Aug 2022908530
Sep 2022807535
Oct 2022817824
Nov 2022817828
Dec 2022555636
Jan 202311811223
Feb 2023615921
Mar 2023757130
Apr 2023645627
May 2023676215
Jun 2023686731
Jul 2023686623
Aug 2023819433
Sep 2023777320
Oct 2023878532
Nov 202315915727
Dec 202312111820
Jan 2024774028
Feb 2024484532
Mar 2024484658
Apr 202412011435
May 2024676140
Jun 2024614522
Jul 2024504718
Aug 2024424124
Sep 2024292819
Total541251962936